Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal TumorsReport as inadecuate




Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors - Download this document for free, or read online. Document in PDF available to download.

Molecular Diagnosis and Therapy

, Volume 17, Issue 1, pp 9–19

Recommendations for Patient Selection, Risk Assessment, and Molecular Response MonitoringFirst Online: 26 January 2013

Abstract

On the basis of the recently published results of a clinical trial comparing 12 and 36 months of imatinib in adjuvant therapy for gastrointestinal stromal tumors GISTs, which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall survival, both the US Food and Drug Administration and the European Medicines Agency have updated their recommendations and approved 36 months of imatinib treatment in patients with v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog KIT-positive GISTs also known as CD117-positive GISTs at high risk of recurrence after surgical resection of a primary tumor. This article discusses patient selection criteria for extended adjuvant therapy with imatinib, different classifications of risk of recurrence, and assessment of the response to therapy.

Download fulltext PDF



Author: Piotr Rutkowski - Joanna Przybył - Marcin Zdzienicki

Source: https://link.springer.com/







Related documents